Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House

Executive Summary

With the Trump administration ahead, CHPA's highest regulatory priorities include eliminating a requirement from the Obama era that consumers get a prescription in order to pay for OTC drugs with pre-tax savings accounts and improving the Nixon-era monograph program.


Related Content

Cosmetics Reg Reform Ill-Situated As Trump, FDA Explore 'Burden Reduction'
Got Ideas For Reducing Industry's Regulatory Burden? FDA Wants To Know
OTC Monograph Reform, User Fee Legislation Coming 'Any Day' – CHPA
Trump’s ACA Repeal: What’s In It For Biopharma?
US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
Indiana Ups State Power To Limit Pseudoephedrine Product Sales
FDA Adds OTC Monograph Staff By Shifting CDER Appropriations
Direct OTC Purchases With Pre-Tax Savings Accounts Passes House
CHPA Makes Take-Back Programs Top Policy Targets Outside Washington
Hearing Targets OTC Eligibility For Health Savings Funds





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts